Literature DB >> 16304374

Molecular Pathogenesis of MDS.

A Thomas Look1.   

Abstract

Clonal disorders of hematopoiesis, such as myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), affect both hematopoietic stem cells and progenitor cells within the erythroid, platelet and granulocytic lineages and can have devastating consequences in children and adults. The genetic features of these diseases often include clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-, 20q-, 6q-, 11q- and 13q-) that appear to inactivate tumor suppressor genes required for the normal development of myeloid cells (reviewed in Bench and Fenaux). These putative tumor suppressors have proved to be much more difficult to identify than oncogenes activated by chromosomal translocations, the other major class of chromosomal lesions in MDS and MPD. Although MDS and MPD are almost certainly caused by mutations in stem/progenitor cells, the role of inactivated tumor suppressor genes in this process remains poorly understood. In a small portion of myeloid diseases, mutations have been identified in genes encoding factors known to be required for normal hematopoiesis, such as PU.1, RUNX1, CTNNA1 (alpha-catenin) and c/EBPalpha, and implicating these genes as tumor suppressors. Nonetheless, the identities of most deletion-associated tumor suppressors in these diseases remains elusive, despite complete sequencing of the human genome. The deleted regions detected by cytogenetic methods are generally very large, containing many hundreds of genes, thus making it hard to locate the critical affected gene or genes. It is also unclear whether dysfunctional myelopoiesis results from haploinsufficiency, associated with the deletion of one allele, or from homozygous inactivation due to additional point mutations or microdeletions of the retained wild-type allele. In general MDS have proved surprisingly resistant to conventional treatments. Targeted therapeutic advances in MDS will likely depend on a full comprehension of underlying molecular mechanisms, in particular the tumor suppressor genes lost through clonal, nonrandom chromosomal deletions, such as the 7q- and (del)5q.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304374     DOI: 10.1182/asheducation-2005.1.156

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  14 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

2.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

Review 3.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.

Authors:  Michaela Dostalova Merkerova; Zdenek Krejcik; Hana Votavova; Monika Belickova; Alzbeta Vasikova; Jaroslav Cermak
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

5.  Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.

Authors:  S Wei; X Chen; K McGraw; L Zhang; R Komrokji; J Clark; G Caceres; D Billingsley; L Sokol; J Lancet; N Fortenbery; J Zhou; E A Eksioglu; D Sallman; H Wang; P K Epling-Burnette; J Djeu; M Sekeres; J P Maciejewski; A List
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867

6.  Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression.

Authors:  Jennifer Rhodes; Adam Amsterdam; Takaomi Sanda; Lisa A Moreau; Keith McKenna; Stefan Heinrichs; Neil J Ganem; Karen W Ho; Donna S Neuberg; Adam Johnston; Yebin Ahn; Jeffery L Kutok; Robert Hromas; Justin Wray; Charles Lee; Carly Murphy; Ina Radtke; James R Downing; Mark D Fleming; Laura E MacConaill; James F Amatruda; Alejandro Gutierrez; Ilene Galinsky; Richard M Stone; Eric A Ross; David S Pellman; John P Kanki; A Thomas Look
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

Review 7.  Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Authors:  Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

8.  Mitoquinone restores platelet production in irradiation-induced thrombocytopenia.

Authors:  Haley Ramsey; Qi Zhang; Mei X Wu
Journal:  Platelets       Date:  2014-07-15       Impact factor: 3.862

9.  Biclonal myelodysplastic syndrome involving six chromosomes and monoallelic loss of RB1 - A rare case.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Elisabeth Klein; Abdulmunim Aljapawe
Journal:  Mol Cytogenet       Date:  2011-08-18       Impact factor: 2.009

10.  Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.

Authors:  Mark A Dickson; Esperanza B Papadopoulos; Cyrus V Hedvat; Suresh C Jhanwar; Renier J Brentjens
Journal:  Leuk Res Rep       Date:  2014-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.